Better Therapeutics, in collaboration with Colorado Prevention Center (CPC) Clinical Research, has recruited the first patient in a real-world evidence study of its prescription digital therapeutic (PDT) called BT-001.

The real-world evidence study is designed to assess the long-term effectiveness and healthcare utilisation changes associated with the use of BT-001 in the treatment of type 2 diabetes.

Better Therapeutics is enrolling patients with type 2 diabetes from the University of Colorado Health System in the open-label, randomised and controlled study.

The multi-year study will assess the use of BT-001 in a diverse patient population and real-world clinical setting.

The cognitive behavioral therapy provided by Better Therapeutics’ PDT is designed to allow changes in neural pathways of the brain to make lasting changes in behaviour possible.

Better Therapeutics chief medical officer Dr Mark Berman said: “Today’s announcement marks the second real-world study collaborator initiating enrollment within the last six months and an important milestone for Better Therapeutics.

“CPC’s contribution to our multi-year real world evidence study will generate robust data demonstrating the potential to improve and maintain glycemic control and reduce ongoing healthcare costs and medications that payers can use to assess for coverage reimbursement.”

Better Therapeutics is engaged in the development of a novel form of cognitive behavioural therapy for cardiometabolic diseases.

The company has designed an advanced platform to develop FDA-regulated and software-based solutions for type 2 diabetes, heart disease and other conditions.

Its clinically validated mobile applications are designed for prescription by physicians and reimbursement like traditional medicines.